Amgen and AstraZeneca Combo Shows Survival Benefit in Lung Cancer

Key Facts

1The combination of Imdelltra and Imfinzi showed survival benefits in patients with extensive-stage small cell lung cancer (ES-SCLC).

In a move that strengthens innovation within the global healthcare sector, Amgen and AstraZeneca reported positive clinical data regarding a combination therapy for lung cancer patients. According to reports, the combination of Imdelltra and Imfinzi showed survival benefits in patients with extensive-stage small cell lung cancer (ES-SCLC). The study aims to broaden the clinical application and market reach of both drugs by proving their efficacy as a first-line treatment option.

This development reflects the high competitiveness in the mega-cap pharma sector as companies strive to enhance their oncology portfolios. Per market data, AMGN shares closed at $391.27, while AZN shares stood at $156.94 (close of September 9, 2026). Positive results from combination drug trials typically support long-term revenue outlooks for major pharmaceutical firms as they continue to seek advanced therapeutic solutions.

Investors should monitor current price levels, as AMGN reached a day high of $395.55 on September 9, 2026, while AZN touched $159.13 on the same day. With no direct healthcare sector catalysts in the upcoming economic calendar, focus remains on future regulatory developments and approvals for this drug combination as a medium-term driver for stock performance.